Navigation Links
Wearing No-line Bifocals Slows Myopia Progression in Some Children

Certain children who wear a special kind of no-line bifocal lenses show signs of slower progression of myopia than those who wear more conventional lenses according to a new// study published in the February 2007 issue of Investigative Ophthalmology & Visual Science (IOVS).

The study found that among children with two myopic parents, myopia progression was slower in children wearing progressive-addition lenses (PALs) when compared to those wearing single-vision lenses (SVLs). Knowing parental myopia may be helpful when deciding which myopic children are likely to benefit from special lenses.

Participants in this study were 232 of the 469 children aged 11 to 16 recruited for the Correction of Myopia Evaluation Trial (COMET). Among the children included in this study, 87 (37.5 percent) had two myopic parents.

“This study shows that parental refractive error should now be added to the constellation of factors which are related to the progression of juvenile onset myopia,” said researcher Dan Kurtz of the New England College of Optometry.

Source-Newswise
SR
'"/>




Page: 1

Related medicine news :

1. Stroke Patients May Benefit By Wearing Cooling Helmets
2. Wearing High Heels May Be Dangerous To Health
3. Masking A Flu? – Wearing Masks, Only Way to Contain It’s Spred
4. Breast Cancer and Bra Wearing: Possibly Linked
5. Beyond Bifocals: Wavefront Technology Benefits Patients With Presbyopia
6. Sox 18 Slows Cancers
7. Early Diagnosis and Treatment Slows Progression of Dementia
8. MRIs Show Drug Treatment Slows Brain Deterioration on Road to Alzheimers Disease
9. AIDS Pandemic Slows Population Growth In South Africa
10. Drug Treatment Slows Macular Vision Loss in Diabetics
11. Learning Slows Physical Progression of Alzheimers Disease: Study
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one ... video series titled The Thyroid Secret. Dr. Wentz talked about journey and research recently ... fact that medication IS NOT the only solution to deal with thyroid disease. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... and by physicians, announced today the launch of a free, public-facing tool for ... Cost Analyzer (VCA) was developed to provide comparative information to patients, providers, insurers ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the ... headquarters to a new, more expansive office space in order to accommodate its ... a distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/27/2017)... 2017 Therapix Biosciences Ltd. ... in the development of cannabinoid-based drugs, today announced ... the United States of 2,000,000 ... ordinary shares of the Company, at a price ... granted the underwriters a 45-day over-allotment option to ...
Breaking Medicine Technology: